Trial Profile
Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Plasmablastic lymphoma
- Focus Therapeutic Use
- 05 Apr 2023 Status changed from active, no longer recruiting to completed.
- 26 May 2020 Results evaluating whether Risk-adapted DA-EPOCH-R therapy is effective and safe in adult Burkitt lymphoma regardless of age or HIV status, published in the Journal of Clinical Oncology
- 17 May 2017 Status changed from recruiting to active, no longer recruiting.